Literature DB >> 26923710

Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant.

Jiangtao Lei1, Ruxi Qi1, Guanghong Wei1, Ruth Nussinov2, Buyong Ma3.   

Abstract

Recent studies suggested that p53 aggregation can lead to loss-of-function (LoF), dominant-negative (DN) and gain-of-function (GoF) effects, with adverse cancer consequences. The p53 aggregation-nucleating (251)ILTIITL(257) fragment is a key segment in wild-type p53 aggregation; however, an I254R mutation can prevent it. It was suggested that self-assembly of wild-type p53 and its cross-interaction with mutants differ from the classical amyloid nucleation-growth mechanism. Here, using replica exchange molecular dynamics (REMD) simulations, we studied the cross-interactions of this p53 core fragment and its aggregation rescue I254R mutant. We found that the core fragment displays strong aggregation propensity, whereas the gatekeeper I254R mutant tends to be disordered, consistent with experiments. Our cross-interaction results reveal that the wild-type p53 fragment promotes β-sheet formation of the I254R mutant by shifting the disordered mutant peptides into aggregating states. As a result, the system has similar oligomeric structures, inter-peptide interactions and free energy landscape as the wild type fragment does, revealing a prion-like process. We also found that in the cross-interaction system, the wild-type species has higher tendency to interact with the mutant than with itself. This phenomenon illustrates synergistic effects between the p53 (251)ILTIITL(257) fragment and the mutant resembling prion cross-species propagation, cautioning against exploiting it in drug discovery.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26923710      PMCID: PMC6456058          DOI: 10.1039/c5cp06538k

Source DB:  PubMed          Journal:  Phys Chem Chem Phys        ISSN: 1463-9076            Impact factor:   3.676


  67 in total

1.  Exploring the energy landscape of a beta hairpin in explicit solvent.

Authors:  A E García; K Y Sanbonmatsu
Journal:  Proteins       Date:  2001-02-15

Review 2.  From p63 to p53 across p73.

Authors:  S Strano; M Rossi; G Fontemaggi; E Munarriz; S Soddu; A Sacchi; G Blandino
Journal:  FEBS Lett       Date:  2001-02-16       Impact factor: 4.124

3.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

4.  Accelerated Poisson-Boltzmann calculations for static and dynamic systems.

Authors:  Ray Luo; Laurent David; Michael K Gilson
Journal:  J Comput Chem       Date:  2002-10       Impact factor: 3.376

5.  How many mutant p53 molecules are needed to inactivate a tetramer?

Authors:  Wan Mui Chan; Wai Yi Siu; Anita Lau; Randy Y C Poon
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

6.  GROMACS: fast, flexible, and free.

Authors:  David Van Der Spoel; Erik Lindahl; Berk Hess; Gerrit Groenhof; Alan E Mark; Herman J C Berendsen
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

Review 7.  Rescuing the function of mutant p53.

Authors:  A N Bullock; A R Fersht
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

8.  Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.

Authors:  Sabrina Strano; Giulia Fontemaggi; Antonio Costanzo; Maria Giulia Rizzo; Olimpia Monti; Alessia Baccarini; Giannino Del Sal; Massimo Levrero; Ada Sacchi; Moshe Oren; Giovanni Blandino
Journal:  J Biol Chem       Date:  2002-03-13       Impact factor: 5.157

9.  Fibrillar aggregates of the tumor suppressor p53 core domain.

Authors:  Daniella Ishimaru; Leonardo R Andrade; Luciano S P Teixeira; Pablo A Quesado; Larissa M Maiolino; Priscila M Lopez; Yraima Cordeiro; Lilian T Costa; Wolfgang M Heckl; Gilberto Weissmüller; Debora Foguel; Jerson L Silva
Journal:  Biochemistry       Date:  2003-08-05       Impact factor: 3.162

10.  Unfolding, aggregation, and amyloid formation by the tetramerization domain from mutant p53 associated with lung cancer.

Authors:  Yuichiro Higashimoto; Yuya Asanomi; Satoru Takakusagi; Marc S Lewis; Kohei Uosaki; Stewart R Durell; Carl W Anderson; Ettore Appella; Kazuyasu Sakaguchi
Journal:  Biochemistry       Date:  2006-02-14       Impact factor: 3.162

View more
  8 in total

1.  Deciphering the mechanisms of HPV E6 mutations in the destabilization of E6/E6AP/p53 complex.

Authors:  Le Li; Xuewei Dong; Yiming Tang; Zenghui Lao; Xuhua Li; Jiangtao Lei; Guanghong Wei
Journal:  Biophys J       Date:  2022-03-29       Impact factor: 3.699

2.  Investigating the Influence of Magnesium Ions on p53-DNA Binding Using Atomic Force Microscopy.

Authors:  Yang Chen; Tianyong Gao; Yanwei Wang; Guangcan Yang
Journal:  Int J Mol Sci       Date:  2017-07-21       Impact factor: 5.923

3.  Assemblies of amyloid-β30-36 hexamer and its G33V/L34T mutants by replica-exchange molecular dynamics simulation.

Authors:  Zhenyu Qian; Qingwen Zhang; Yu Liu; Peijie Chen
Journal:  PLoS One       Date:  2017-11-29       Impact factor: 3.240

4.  Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds.

Authors:  Elio A Cino; Iaci N Soares; Murilo M Pedrote; Guilherme A P de Oliveira; Jerson L Silva
Journal:  Sci Rep       Date:  2016-09-07       Impact factor: 4.379

5.  Unraveling the Influence of K280 Acetylation on the Conformational Features of Tau Core Fragment: A Molecular Dynamics Simulation Study.

Authors:  Yu Zou; Lulu Guan
Journal:  Front Mol Biosci       Date:  2021-12-13

6.  Insights into Allosteric Mechanisms of the Lung-Enriched p53 Mutants V157F and R158L.

Authors:  Jiangtao Lei; Xuanyao Li; Mengqiang Cai; Tianjing Guo; Dongdong Lin; Xiaohua Deng; Yin Li
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

Review 7.  p53 Isoforms and Their Implications in Cancer.

Authors:  Maximilian Vieler; Suparna Sanyal
Journal:  Cancers (Basel)       Date:  2018-08-25       Impact factor: 6.639

8.  Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC.

Authors:  Yaqun Zhang; Lingfan Xu; Yan Chang; YanJing Li; William Butler; Er Jin; Aifen Wang; Yulei Tao; Xufeng Chen; Chaozhao Liang; Jiaoti Huang
Journal:  Prostate Cancer Prostatic Dis       Date:  2019-08-30       Impact factor: 5.554

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.